IDEAYA Biosciences, Inc. Increase (Decrease) in Contract with Customer, Liability
IDEAYA Biosciences, Inc. (IDYA) reported Increase (Decrease) in Contract with Customer, Liability of -$587.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-05-05
- IDEAYA Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$587.00K.
- IDEAYA Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-03-31 was $0.00.
- IDEAYA Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-12-31 was $0.00.
- IDEAYA Biosciences, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2024-09-30 was $0.00.
- IDEAYA Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
- IDEAYA Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$13.75M.
- IDEAYA Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$46.48M.
- IDEAYA Biosciences, Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$23.54M, a 128.10% decline from fiscal 2020.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$587.00K 10-Q · filed 2026-05-05 | |||
| 2025-09-30 | $2.17M 10-Q · filed 2025-11-04 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-05 | $0.00 derived: sum of 2 quarters · filed 2026-05-05 | $0.00 derived: sum of 3 quarters · filed 2026-05-05 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $0.00 derived: sum of 2 quarters · filed 2025-02-18 | $0.00 10-K · filed 2025-02-18 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | |||
| 2023-12-31 | -$1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$2.82M derived: sum of 2 quarters · filed 2025-02-18 | -$6.25M derived: sum of 3 quarters · filed 2025-02-18 | -$13.75M 10-K · filed 2025-02-18 |
| 2023-09-30 | -$1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$4.82M derived: sum of 2 quarters · filed 2024-11-04 | -$12.31M 10-Q · filed 2024-11-04 | -$16.14M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | -$3.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$10.94M 10-Q · filed 2024-08-06 | -$14.76M derived: sum of 3 quarters · filed 2025-02-18 | -$41.06M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | -$7.50M 10-Q · filed 2024-05-07 | -$11.33M derived: sum of 2 quarters · filed 2025-02-18 | -$37.62M derived: sum of 3 quarters · filed 2025-02-18 | -$43.18M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | -$3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$30.12M derived: sum of 2 quarters · filed 2025-02-18 | -$35.68M derived: sum of 3 quarters · filed 2025-02-18 | -$46.48M 10-K · filed 2025-02-18 |
| 2022-09-30 | -$26.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$31.86M derived: sum of 2 quarters · filed 2023-11-07 | -$42.65M 10-Q · filed 2023-11-07 | -$44.60M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$5.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$16.36M 10-Q · filed 2023-08-10 | -$18.31M derived: sum of 3 quarters · filed 2024-02-20 | -$26.27M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | -$10.80M 10-Q · filed 2023-05-09 | -$12.75M derived: sum of 2 quarters · filed 2024-02-20 | -$20.70M derived: sum of 3 quarters · filed 2024-02-20 | -$28.14M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | -$1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$9.91M derived: sum of 2 quarters · filed 2024-02-20 | -$17.34M derived: sum of 3 quarters · filed 2024-02-20 | -$23.54M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$7.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$15.39M derived: sum of 2 quarters · filed 2022-11-08 | -$21.59M 10-Q · filed 2022-11-08 | -$28.85M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | -$7.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$13.63M 10-Q · filed 2022-08-15 | -$20.89M derived: sum of 3 quarters · filed 2023-03-07 | |
| 2021-03-31 | -$6.20M 10-Q · filed 2022-05-10 | -$13.46M derived: sum of 2 quarters · filed 2023-03-07 | ||
| 2020-12-31 | -$7.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $83.77M 10-K · filed 2023-03-07 | ||
| 2020-09-30 | $91.03M 10-Q · filed 2021-11-15 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |